Oncode Accelerator announces first call opening
After 1.5 years of laying a solid foundation for its unique preclinical cancer therapy development infrastructure, Oncode Accelerator announces the opening of its first call for Demonstrator Projects. Interested parties can be eligible for co-funding of their project.
‘This is a game-changer for the Dutch cancer therapy development landscape’, Arnoud Huisman, CEO of Oncode Accelerator, says. He refers to the innovative approach of Oncode Accelerator, integrating cancer therapy development pipelines with the three Oncode Accelerator Innovation Platforms: well-defined patient cohorts, organoid models, and artificial intelligence. Huisman: ‘Together with partners from academia and industry, we aim to accelerate and derisk the preclinical phase of cancer therapy development.’
Co-funding opportunities available
The call opening means that Oncode Accelerator invites all interested parties to apply for so-called Demonstrator Projects. Demonstrator Projects aim to test and validate the innovated Oncode Accelerator infrastructure, and to develop clinical candidates that can ultimately provide new therapeutic solutions for cancer patients. ‘It is our goal to deliver potential therapies which are ready to enter the clinical phase’, Huisman explains.
‘It is our goal to deliver potential therapies which are ready to enter the clinical phase’
Arnoud Huisman, Oncode Accelerator CEO
Through the Oncode Accelerator infrastructure, applicants will be eligible for up to 50% co-funding (maximum of €1.5 million per Demonstrator Project) by the Dutch National Growth Fund. During the first call phase, lasting until Q2 of 2025, a total co-funding budget of €25 million is available. The Oncode Accelerator team and an independent advisory board will help manage the process, monitor progress, and determine eligibility and continuation.
Why work with Oncode Accelerator?
Working with them grants access to the Oncode Accelerator research infrastructure, which comprises over 30 partners, including universities, university medical centers, pharmaceutical companies, and more. It is coordinated by Oncode Accelerator Foundation, consisting of a team of project managers, business developers, communication specialists, senior management, and more. Together, they cover the entire spectrum of preclinical cancer therapy development.
As a partner of their unique cancer research network, you will thus have access to state-of-the-art equipment, world-class research institutes and industry, top scientists, and a dedicated team to manage the process from start to finish.
What’s in it for you?
- Co-funding for eligible Demonstrator Projects.
- Access to the latest innovations in discovery & preclinical development.
- Access to well-defined patient cohorts, patient data and patient-derived models.
- Better prediction of efficacy and safety using AI.
- Accelerated development of de-risked clinical candidates.
- Integrated approach in executing Demonstrator Projects.
Interested parties are invited to contact their Business Development Team. More information can be found on their website, including the intake and selection process, requirements, and much more.
Source: Oncode Accelerator
